Key result
Ibopamine appears to have beneficial hemodynamic, renal, and neurohormonal effects in chronic heart failure, but large-scale trials are needed to assess its effects on morbidity and mortality.
Why the study?
Does ibopamine improve symptoms, functional capacity, and survival in patients with chronic heart failure when added to standard therapy?
Does ibopamine improve symptoms, functional capacity, and survival in patients with chronic heart failure when added to standard therapy?
Ibopamine shows potential as an adjunctive therapy in chronic heart failure, but large-scale trials are required to confirm its effects on morbidity and mortality.
May support adjunctive investigation in chronic HF; should not yet change practice pending large outcome trials.
Ibopamine, the most widely studied dopaminergic drug for the treatment of chronic heart failure, appears to have beneficial hemodynamic, renal, and neurohormonal effects in this setting. Angiotension-converting enzyme (ACE) inhibitors have become the recommended standard treatment for chronic heart failure; however, some patients may benefit from additional drugs to improve their symptoms and functional capacity. Ibopamine may be effective as an additive drug for patients with chronic heart failure. It is also possible that ibopamine will improve survival in these patients. Large-scale trials are needed to assess the effects on morbidity and mortality when ibopamine is added to ACE inhibitors, diuretics, and possibly digitalis.
No takes yet. Share an insight, caveat, or question.
Metra et al. (1995) conducted a review in chronic heart failure. Ibopamine was evaluated. Ibopamine appears to have beneficial hemodynamic, renal, and neurohormonal effects in chronic heart failure, but large-scale trials are needed to assess its effects on morbidity and mortality.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: